StockData
ProMIS Neurosciences Inc. logo

ProMIS Neurosciences Inc. (PMN) stock

PMNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$3.29−0.19 (-5.46%)

Close on Nov 13, 2026Market cap $29.50MP/E –Yield –

ProMIS Neurosciences r&d expenses

Research and development expenses are spending on new products and technology.

ProMIS Neurosciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $32.57M, up 14.9% year over year. For fiscal 2025 it was $33.38M, up 213.8% from the year before. The highest annual figure on record is $33.38M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$33.38M+213.8%
FY2024Dec 31, 2024$10.64M+34.9%
FY2023Dec 31, 2023$7.88M-51.0%
FY2022Dec 31, 2022$16.09M+247.7%
FY2021Dec 31, 2021$4.63M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$6.71M-31.5%
Q2 FY2026Jun 30, 2026$9.52M+8.8%
Q1 FY2026Mar 31, 2026$6.97M+27.6%
Q4 FY2025Dec 31, 2025$9.37M+116.6%
Q3 FY2025Sep 30, 2025$9.80M+282.1%
Q2 FY2025Jun 30, 2025$8.75M+438.2%
Q1 FY2025Mar 31, 2025$5.46M+157.3%
Q4 FY2024Dec 31, 2024$4.32M+94.4%
Q3 FY2024Sep 30, 2024$2.56M+124.5%
Q2 FY2024Jun 30, 2024$1.63M+61.7%
Q1 FY2024Mar 31, 2024$2.12M-39.5%
Q4 FY2023Dec 31, 2023$2.23M-65.1%
Q3 FY2023Sep 30, 2023$1.14M-75.0%
Q2 FY2023Jun 30, 2023$1.01M-68.9%
Q1 FY2023Mar 31, 2023$3.51M+84.5%
Q4 FY2022Dec 31, 2022$6.38M+124.2%
Q3 FY2022Sep 30, 2022$4.57M+467.5%
Q2 FY2022Jun 30, 2022$3.23M+328.2%
Q1 FY2022Mar 31, 2022$1.90M–
Q4 FY2021Dec 31, 2021$2.85M–
Q3 FY2021Sep 30, 2021$805.39K–
Q2 FY2021Jun 30, 2021$754.30K–

More ProMIS Neurosciences figures

See a number that looks wrong?